jeffrey weber, md, phd: second-line therapy
Published 7 years ago • 34 plays • Length 1:17
Download video MP4
Download video MP3
Similar videos
-
1:01
jeffrey weber, md, phd: durability of a response to targeted therapy combination
-
1:44
jeffrey weber, md, phd: predicting durable responses to targeted therapy
-
1:23
dr. jeffrey weber on the keys to targeted treatments
-
2:20
jeffrey weber, md, phd: the association between durable response and low disease burden
-
1:11
jeffrey weber, md, phd: the impact of moderate level of disease burden
-
0:57
jeffrey weber, md, phd: the role of ldh, age, and sites of disease in durability of response
-
6:16
dr. jeffrey weber, md, phd at laura & isaac perlmutter cancer center and academy of immuno-oncology
-
2:19
jeffrey weber, md, phd: factors to consider when determining treatment
-
2:34
jeffrey weber, md, phd explains the importance of administering ipilimumab with a pd-l1 inhibitor
-
0:49
dr. weber on emerging therapies in melanoma
-
1:23
jeffrey weber, md, phd discusses the long term side effects with immunotherapies
-
2:26
jeffrey weber, md, phd explains the long term data from keynote-001 study in advanced melanoma
-
0:42
2022 ime dr. jeffrey s. weber, md, phd invites you to the 18th annual ime conference on melanoma
-
1:08
dr. weber discusses toxicity of immunotherapies in melanoma
-
1:44
dr. jeffrey weber on optimal therapy sequences in advanced melanoma
-
1:26
jeffrey weber, md, phd provides interpretation of the nemo trial results
-
2:58
dr. weber on the importance of an nci spore grant
-
2:10
dr. jeffrey s. weber on why the results of checkmate-064 were surprising
-
1:50
dr. weber discusses updated data for checkmate-238
Clip.africa.com - Privacy-policy